Leticia De Mattos-Arruda

Summary

Affiliation: Hospital Universitari Vall d'Hebron
Country: Spain

Publications

  1. doi request reprint Circulating tumour cells and cell-free DNA as tools for managing breast cancer
    Leticia De Mattos-Arruda
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Paseo Vall d Hebron 119 129, 08035 Barcelona, Spain
    Nat Rev Clin Oncol 10:377-89. 2013
  2. doi request reprint Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer
    Leticia De Mattos-Arruda
    Medical Oncology Department, Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Adv Ther 30:645-58. 2013
  3. doi request reprint Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype?
    Leticia De Mattos-Arruda
    Medical Oncology Department, Vall d Hebron University Hospital, Paseo Vall d Hebron 119 129, 08035 Barcelona, Spain
    Breast 21:604-7. 2012
  4. pmc Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma
    Leticia De Mattos-Arruda
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, P Vall d Hebron 119 129, 08035 Barcelona, Spain
    Nat Commun 6:8839. 2015
  5. pmc Advances in first-line treatment for patients with HER-2+ metastatic breast cancer
    Leticia De Mattos-Arruda
    Medical Oncology Department, Vall d Hebron University Hospital, Barcelona, Spain
    Oncologist 17:631-44. 2012
  6. doi request reprint Cell-free circulating tumour DNA as a liquid biopsy in breast cancer
    Leticia De Mattos-Arruda
    Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Barcelona, Spain Universitat Autònoma de Barcelona, Barcelona, Spain
    Mol Oncol 10:464-74. 2016
  7. pmc MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients
    Leticia De Mattos-Arruda
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Oncotarget 6:37269-80. 2015
  8. doi request reprint Brain metastasis: new opportunities to tackle therapeutic resistance
    Joan Seoane
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Barcelona, Spain Universitat Autònoma de Barcelona, Barcelona, Spain Institució Catalana de Recerca i Estudis Avançats ICREA, Barcelona, Spain Electronic address
    Mol Oncol 8:1120-31. 2014
  9. doi request reprint Escaping out of the brain
    Joan Seoane
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Barcelona, Spain Universitat Autònoma de Barcelona, Barcelona, Spain Institució Catalana de Recerca i Estudis Avançats ICREA, Barcelona, Spain
    Cancer Discov 4:1259-61. 2014
  10. doi request reprint Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing
    Leticia De Mattos-Arruda
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Barcelona, Spain Universitat Autònoma de Barcelona, Barcelona, Spain
    Mol Oncol 8:150-8. 2014

Detail Information

Publications10

  1. doi request reprint Circulating tumour cells and cell-free DNA as tools for managing breast cancer
    Leticia De Mattos-Arruda
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Paseo Vall d Hebron 119 129, 08035 Barcelona, Spain
    Nat Rev Clin Oncol 10:377-89. 2013
    ..In this Review, we discuss the current status of blood-born biomarkers as surrogates for tissue-based biomarkers, and their burgeoning impact on the management of patients with breast cancer. ..
  2. doi request reprint Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer
    Leticia De Mattos-Arruda
    Medical Oncology Department, Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Adv Ther 30:645-58. 2013
    ..Pertuzumab, a HER2-targeted monoclonal antibody that prevents HER2 dimerisation, is the first of a class of promising targeted agents for the treatment of HER2-positive breast cancer...
  3. doi request reprint Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype?
    Leticia De Mattos-Arruda
    Medical Oncology Department, Vall d Hebron University Hospital, Paseo Vall d Hebron 119 129, 08035 Barcelona, Spain
    Breast 21:604-7. 2012
    ..In this article, we revisit HSP90 inhibitors in the context of breast cancer and discuss some notable preclinical data that reveal potential roles in both hormonal receptor-positive and triple negative breast tumor subtypes...
  4. pmc Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma
    Leticia De Mattos-Arruda
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, P Vall d Hebron 119 129, 08035 Barcelona, Spain
    Nat Commun 6:8839. 2015
    ..Moreover, CSF ctDNA is shown to facilitate and complement the diagnosis of leptomeningeal carcinomatosis. ..
  5. pmc Advances in first-line treatment for patients with HER-2+ metastatic breast cancer
    Leticia De Mattos-Arruda
    Medical Oncology Department, Vall d Hebron University Hospital, Barcelona, Spain
    Oncologist 17:631-44. 2012
    ..Although anti-HER-2 therapy with trastuzumab and chemotherapy is the standard first-line treatment, the best therapeutic regimen has yet to be defined, and new strategies are evolving...
  6. doi request reprint Cell-free circulating tumour DNA as a liquid biopsy in breast cancer
    Leticia De Mattos-Arruda
    Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Barcelona, Spain Universitat Autònoma de Barcelona, Barcelona, Spain
    Mol Oncol 10:464-74. 2016
    ..In this article, we review the current status of ctDNA as a 'liquid biopsy' in breast cancer. ..
  7. pmc MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients
    Leticia De Mattos-Arruda
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Oncotarget 6:37269-80. 2015
    ....
  8. doi request reprint Brain metastasis: new opportunities to tackle therapeutic resistance
    Joan Seoane
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Barcelona, Spain Universitat Autònoma de Barcelona, Barcelona, Spain Institució Catalana de Recerca i Estudis Avançats ICREA, Barcelona, Spain Electronic address
    Mol Oncol 8:1120-31. 2014
    ..In this article, we review current knowledge of the unique characteristics of brain metastasis, implications in therapeutic resistance, and the possibility of developing biomarkers to rationally guide the use of targeted agents. ..
  9. doi request reprint Escaping out of the brain
    Joan Seoane
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Barcelona, Spain Universitat Autònoma de Barcelona, Barcelona, Spain Institució Catalana de Recerca i Estudis Avançats ICREA, Barcelona, Spain
    Cancer Discov 4:1259-61. 2014
    ..This opens a new avenue of research with implications for the understanding and clinical managing of this fatal disease...
  10. doi request reprint Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing
    Leticia De Mattos-Arruda
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Barcelona, Spain Universitat Autònoma de Barcelona, Barcelona, Spain
    Mol Oncol 8:150-8. 2014
    ....